Roche and Biotie's inflammation antibody deal breaks up
This article was originally published in Scrip
Executive Summary
Roche has decided not to exercise its opt-in right for the development and commercialisation of the Finnish company Biotie's novel VAP-1 antibody for inflammatory disease BTT-1023.